Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Targeted cancer therapeutics: the heartbreak of success

Nature Medicine volume 12, pages 881–882 (2006)Cite this article

Tyrosine kinase inhibitors, widely hailed for their success as treatments for cancer, are also plagued by the issue of cardiotoxic side effects. The mechanism behind the heart damage now comes to light for one such inhibitor, imatinib mesylate, also known as Gleevec (pages 908–916).

One of the exciting developments in cancer research has been the clinical validation of drugs that target and inhibit oncogenic tyrosine kinases. Treatment of appropriately selected patients with these agents not only alters the natural history of the disease, but also improves survival. But some of these agents have also been troubled with issues of side effects, particularly traztuzumab (Herceptin, Genentech), which can induce heart damage.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Sustained endoplasmic reticulum stress can lead to apoptosis through several pathways.

Kim Caesar

References

  1. Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).

    Article  CAS  Google Scholar 

  2. Crone, S.A. et al. Nat. Med. 8, 459–465 (2002).

    Article  CAS  Google Scholar 

  3. Kerkelä, R. et al. Nat. Med. 12, 908–916 (2006).

    Article  Google Scholar 

  4. Druker, B.J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).

    Article  CAS  Google Scholar 

  5. Terai, K. et al. Mol. Cell Biol. 25, 9554–9575 (2005).

    Article  CAS  Google Scholar 

  6. Boyce, M. & Yuan, J. Cell Death. Differ. 13, 363–373 (2006).

    Article  CAS  Google Scholar 

  7. Kumar, S. et al. J. Biol. Chem. 276, 17281–17285 (2001).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The author is in the Department of Medicine, Winters Center for Heart Failure Research, Section of Cardiology, Baylor College of Medicine and the Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, 77030, Texas, USA

    Douglas L Mann

Authors
  1. Douglas L Mann
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mann, D. Targeted cancer therapeutics: the heartbreak of success. Nat Med 12, 881–882 (2006). https://doi.org/10.1038/nm0806-881

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0806-881

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing